LIM and calponin homology domains 1Genealiases: LIMCH1A · LMO7B
Q-omics provides the consensus-scored LIMCH1 profile across patient tissues and cancer cell-line models. LIMCH1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LIMCH1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, LIMCH1 protein abundance shows 25,593 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, THCA, and HNSC as cancer lineages where LIMCH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIMCH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIMCH1 survival associations across molecular data types. LIMCH1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIMCH1 RNA expression–survival associations across cancer types. High LIMCH1 expression shows unfavorable associations in UVM, BRCA and KIRP, but favorable associations in KIRC, BLCA and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LIMCH1 RNA expression.
This table summarizes LIMCH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LIMCH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIMCH1 shows lower tumor expression in THCA, KIRC, LUSC, LUAD, HNSC and KIRP. The THCA box plot shows higher LIMCH1 RNA expression in normal versus tumor tissue (log2 FC = −1.542, t-test p < 0.001).
This table shows molecular features associated with LIMCH1 in patient tissues and cancer cell lines. In patient samples, LIMCH1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, LIMCH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
